| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
29,260,000 |
| Market
Cap: |
230.28(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.27 - $9.89 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile XBiotech is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases. Co. has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. An area of medical focus for Co. are therapies that block a substance naturally produced by body, known as interleukin-1 alpha, that mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting and inflammation. Co.'s product development includes: Natrunix program, which is for the indication of pancreatic cancer and rheumatoid arthritis, and Hutrukin program, which is for the indication of stroke.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Waldin Jan-Paul |
Director |
– • – |
2020-02-12 |
4 |
D |
$30.00 |
$2,868,360 |
D/D |
(95,612) |
204,388 |
|
- |
|
| Bay Street Financial S.a. |
10% Owner |
– – • |
2020-02-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000,000 |
|
-41% |
|
| Rennes Foundation |
10% Owner |
– – • |
2020-02-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000,000 |
110,282 |
|
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2020-01-06 |
4 |
OE |
$3.75 |
$461,250 |
D/D |
123,000 |
3,706,600 |
|
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2019-11-29 |
4 |
OE |
$3.75 |
$693,750 |
D/D |
185,000 |
3,583,600 |
|
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2019-09-06 |
4 |
S |
$3.69 |
$26,397 |
D/D |
(7,159) |
3,880,421 |
|
- |
|
| Rennes Foundation |
10% Owner |
– – • |
2019-06-04 |
4 |
B |
$8.25 |
$9,900,000 |
D/D |
1,200,000 |
5,110,282 |
2.45 |
- |
|
| Rennes Foundation |
10% Owner |
– – • |
2019-03-04 |
4 |
B |
$7.91 |
$129,930 |
D/D |
16,426 |
3,910,282 |
2.45 |
- |
|
| Rennes Foundation |
10% Owner |
– – • |
2019-03-01 |
4 |
B |
$8.13 |
$284,542 |
D/D |
34,999 |
3,893,856 |
2.45 |
- |
|
| Rennes Foundation |
10% Owner |
– – • |
2019-02-28 |
4 |
B |
$8.19 |
$43,423 |
D/D |
5,302 |
3,858,857 |
2.37 |
- |
|
| Rennes Foundation |
10% Owner |
– – • |
2019-02-27 |
4 |
B |
$8.13 |
$42,869 |
D/D |
5,273 |
3,853,555 |
2.37 |
- |
|
| Shivaswamy Sushma |
Chief Scientific Officer |
• – – |
2019-02-07 |
4 |
S |
$10.00 |
$45,000 |
D/D |
(4,500) |
0 |
|
- |
|
| Shivaswamy Sushma |
Chief Scientific Officer |
• – – |
2019-02-07 |
4 |
OE |
$2.50 |
$11,250 |
D/D |
4,500 |
4,500 |
|
- |
|
| Rennes Foundation |
10% Owner |
– – • |
2019-02-07 |
4 |
B |
$10.00 |
$400,000 |
D/D |
40,000 |
3,698,282 |
2.45 |
- |
|
| Rennes Foundation |
10% Owner |
– – • |
2019-02-06 |
4 |
B |
$8.93 |
$597,250 |
D/D |
65,000 |
3,658,282 |
2.45 |
- |
|
| Rennes Foundation |
10% Owner |
– – • |
2019-01-02 |
4 |
B |
$5.15 |
$4,635 |
D/D |
900 |
3,593,282 |
2.37 |
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2018-12-27 |
4/A |
B |
$4.92 |
$6,706 |
I/I |
1,364 |
47,738 |
2.17 |
- |
|
| Rennes Foundation |
10% Owner |
– – • |
2018-12-27 |
4 |
B |
$4.98 |
$10,956 |
D/D |
2,200 |
3,592,382 |
2.37 |
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2018-12-27 |
4 |
B |
$4.92 |
$6,706 |
I/I |
1,364 |
32,702 |
2.17 |
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2018-12-26 |
4/A |
B |
$5.07 |
$94,567 |
I/I |
18,636 |
46,374 |
2.25 |
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2018-12-26 |
4 |
B |
$5.00 |
$17,996 |
I/I |
3,600 |
31,338 |
2.17 |
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2018-12-24 |
4 |
B |
$5.88 |
$146,097 |
I/I |
24,838 |
27,738 |
2.25 |
- |
|
| Rennes Foundation |
10% Owner |
– – • |
2018-12-21 |
4 |
B |
$6.24 |
$26,208 |
D/D |
4,200 |
3,590,182 |
2.37 |
- |
|
| Simard John |
Chief Executive Officer |
• • • |
2018-12-19 |
4 |
OE |
$2.50 |
$125,000 |
D/D |
50,000 |
6,327,060 |
|
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2018-11-12 |
4 |
B |
$3.75 |
$2,625 |
I/I |
700 |
2,900 |
2.17 |
- |
|
124 Records found
|
|
Page 3 of 5 |
|
|
0.34 (4.14%) 
